CIRM Funded Clinical Trials

Phase 1/1b study of T-allo10 infusion after HLA-partially matched abdepleted-HSCT in children and young adults with hematologic malignancies.

Disease Area: 
B cell cancers
Leukemia, Acute Myeloid (AML)
CIRM Grant:
Award Value:
$10,563,822
Trial Sponsor:
Stanford University
Trial Stage: 
Phase 1
Trial Status: 
Launching
Targeted Enrollment:
N/A